<DOC>
	<DOCNO>NCT00008177</DOCNO>
	<brief_summary>This phase I trial study side effect best dose iodine I 131 monoclonal antibody BC8 give together fludarabine phosphate low-dose total-body irradiation follow donor stem cell transplant immunosuppression therapy treat old patient acute myeloid leukemia high-risk myelodysplastic syndrome control treatment . Radiolabeled monoclonal antibody , iodine I 131 monoclonal antibody BC8 , find cancer cell carry cancer-killing substance . Giving chemotherapy , fludarabine phosphate , total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer abnormal cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . The donated stem cell may also replace patient 's immune cell help destroy remain cancer cell . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving radiolabeled monoclonal antibody therapy together fludarabine phosphate total-body irradiation transplant together cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy , Fludarabine Phosphate , Low-Dose Total-Body Irradiation Followed Donor Stem Cell Transplant Immunosuppression Therapy Treating Older Patients With Advanced Acute Myeloid Leukemia High-Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose radiation deliver via 131I-BC8 antibody ( iodine I 131 monoclonal antibody BC8 ) combine non-myeloablative regimen fludarabine ( fludarabine phosphate ) , 2 Gy total-body irradiation ( TBI ) + cyclosporine ( CSP ) /mycophenolate ( MMF ) elderly patient advance acute myeloid leukemia ( AML ) high risk myelodysplastic syndrome ( MDS ) . II . To determine rate donor chimerism result combine preparative regimen , correlate level donor chimerism estimate radiation dos deliver hematopoietic tissue via antibody . III . To determine , within limit phase I study , disease response duration remission . IV . To assess dose-limiting toxicity ( DLT ) estimate maximum tolerate dose ( MTD ) 131I-BC8 ( 24 Gy ) order gain confidence DLT rate acceptable level . OUTLINE : This dose-escalation study iodine I 131 monoclonal antibody BC8 . CONDITIONING REGIMEN : Patients receive iodine I 131 monoclonal antibody BC8 intravenously ( IV ) day -12 fludarabine phosphate IV day -4 -2 . Patients undergo total-body irradiation day 0 . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell transplantation day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine orally ( PO ) IV twice daily ( BID ) day -3 56 taper day 80 ( patient relate donor ) OR day -3 100 taper day 177 ( patient unrelated donor ) absence graft-versus-host disease ( GVHD ) . Patients also receive mycophenolate mofetil PO IV thrice daily ( TID ) day 0 27 ( patient relate donor ) OR day 0 40 taper day 96 ( patient unrelated donor ) absence GVHD . After completion study treatment , patient follow 6 , 9 , 12 month , every 6 month 1 year , yearly thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Patients advance AML define beyond first remission , primary refractory disease , evolve myelodysplastic myeloproliferative syndrome ; patient MDS express refractory anemia excess blast ( RAEB ) , refractory anemia excess blast transformation ( RAEBT [ Note : classification remove current World Health Organization [ WHO ] classification system ] ) , refractory cytopenia multilineage dysplasia ( RCMD ) , RCMD ring sideroblast ( RCMDRS ) , chronic myelomonocytic leukemia ( CMML ) Patients relapse must document cluster differentiation ( CD ) 45 expression myelodysplastic leukemic cell study treat 131Ilabeled BC8 antibody ; patient remission require phenotyping may leukemia previously document CD45 negative Patients circulate blast count le 10,000/mm^3 ( control hydroxyurea similar agent allow ) Patients must undergo 24hour urine collection document creatinine clearance &gt; 50 ml/min Bilirubin &lt; 2 time upper limit normal Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2 time upper limit normal Karnofsky score &gt; = 70 Eastern Cooperative Oncology Group ( ECOG ) = &lt; 2 Patients must expect survival &gt; 60 day must free active infection Patients must human leukocyte antigen ( HLA ) identical sibling donor HLAmatched unrelated donor meet standard Seattle Cancer Care Alliance ( SCCA ) and/or National Marrow Donor Program ( NMDP ) criteria peripheral blood stem cell ( PBSC ) donation ; relate donor match molecular method intermediate resolution level HLAA , B , C , DRB1 accord Fred Hutchinson Cancer Research Center ( FHCRC ) Standard Practice Guidelines allele level DQB1 ; unrelated donor identify use match criterion follow FHCRC Standard Practice Guidelines limit study eligible donor allele match HLAA , B , C , DRB1 , DQB1 ( grade 1 ) , accept one allele mismatch per standard practice grade 2.1 HLAA , B , C ; PBSC permit hematopoietic stem cell ( HSC ) source DONOR : Donors must meet HLA match criterion outline well standard Seattle Cancer Care Alliance ( SCCA ) and/or NMDP criterion PBSC donation Circulating antibody mouse immunoglobulin ( human antimouse antibody [ HAMA ] ) Prior radiation maximally tolerated level normal organ Patients may symptomatic coronary artery disease may cardiac medication antiarrhythmic inotropic effect Inability understand give inform consent Patients seropositive human immunodeficiency virus ( HIV ) Perceived inability tolerate diagnostic therapeutic procedure , particularly treatment radiation isolation Patients previously undergone marrow PBSC transplantation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>